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ABSTRACT 
Background: Inorganic fluoride and compound A are potential nephrotoxic 
products of sevoflurane, a halogenated inhalational general-anesthetic drug. 
Objective: The aim of this study was to microscopically examine the effect 
of sevoflurane on the severity of renal histopathologic changes in rabbits pre- 
treated with gentamicin. 
Methods: In this controlled, investigator-blinded, xperimental study at the 
Firat University School of Medicine, Elazig, Turkey, male New Zealand white rab- 
bits (age range, 6-8 months; weight range, 2600-3400 g) were randomly divid- 
ed into 4 groups of equal size. The gentamicin group received IM gentamicin 
10 mg/kg, d -I for 10 days. Rabbits in the sevoflurane group received pH-balanced 
saline solution at a volume of 10 mg/kg • d -1 for 10 days, equivalent to the vol- 
ume of gentamicin administered tothe gentamicin group. On day 11, anesthesia 
was induced with 8% sevoflurane in 50% oxygen and air using a suitable face- 
mask. When a sufficient depth of anesthesia (loss of eyelash reflex and toler- 
ance to tail-clamp stimuli) was reached (without a muscle relaxant), the rabbits 
were intubated (3-mm ID) and allowed to breathe spontaneously. End-tidal or 
end expiratory concentration of sevoflurane was then decreased to 4% and the 
rabbits were anesthetized at a flow rate of 4 L/min for 4 hours. The rabbits in 
the gentamicin +sevoflurane group were treated with IM gentamicin at a dosage 
of 10 mg/kg • d -1 for 10 days. On day 11, they were exposed to sevoflurane, as 
described for the sevofiurane group. The control group received IM pH-balanced 
saline solution for the duration of the study. Twenty-four hours after treatment 
completion, all rabbits were euthanized and kidney tissue samples were obtained. 
Histopathologic examinations were then carried out using light microscopy. 
Changes in renal histopathology were based on the percentage of acute tubular 
necrosis (ATN) and judged on a scale from none to severe. 
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Results: Forty male New Zealand white rabbits (mean [SD] age, 7 [0.49] months; 
mean [SD] weight, 2900 [150] g) were divided into 4 groups of 10 rabbits each. 
Proximal renal tubule cell injury in the form of ATN (the mean score) was signifi- 
cantly greater in the 3 treatment groups than in the control group (all, P < 
0.001), especially at the corticomedullary junction. In the 3 treatment groups, 
the most severe renal damage observed was rated as mild (10%-25%). More 
rabbits in the gentamicin + sevoflurane group had mild renal damage (7) than 
in the gentamicin group (4) or the sevoflurane group (4), but the between-group 
differences were not statistically significant. 
Conclusion: In this experimental study of the effects of sevoflurane on the 
severity of renal histopathologic changes, a higher percentage of rabbits were 
observed to have greater enal damage in the gentamicin ÷ sevoflurane group 
than the other groups. However, between-group differences did not reach sta- 
tistical significance. (Curr TherRes Clin Exp. 2006;67:386-395) Copyright © 2006 
Excerpta Medica, Inc. 
Key words: nephrotoxicity, sevoflurane, gentamicin, histopathology. 
INTRODUCTION 
The kidneys are the organ system that is most impacted, both directly and 
indirectly, by the toxic effects of inhalational general anesthetics. 1 Inorganic 
fluoride, which results from the metabolic biotransformation f sevoflurane by 
human hepatic cytochrome P450 2El, 2 and compound A (CF2--C[CF3]OCH2F), 
which results from degradation of sevoflurane by CO 2 absorbents in the anes- 
thesia circuit, 3 are potentially nephrotoxic. Inorganic fluoride-induced nephro- 
toxicity has been reported in both animals and humans after anesthesia 
induced by methoxyflurane or enflurane. 4-6 In rats, compound A has been 
associated with nephrotoxicity, causing dose- and duration-dependent proxi- 
mal tubular necrosis. 7,8 However, the nephrotoxic effect of sevoflurane in 
humans is controversial. Many studies of the nephrotoxicity of sevoflurane 
using biochemical markers of renal function and injury have been carried out 
in humans. Some authors have reported that no evidence of sevoflurane- 
related renal injury or dysfunction was observed. 6,9 In the study by Ebert et al, 9 
an 8-hour administration of sevoflurane 3% in a fresh gas flow of 2 L/min to 
13 healthy male volunteers did not result in clinically significant changes in 
biochemical markers of renal or hepatic dysfunction. However, other investi- 
gators have found that sevoflurane was associated with transient renal injury 
or abnormal changes in renal function. 1°,11 In the study by Higuchi et al, 1° ad- 
ministration of low-flow sevoflurane (1 L/min) was associated with signifi- 
cant increases of several biochemical markers in half of the 64 elective surgi- 
cal patients when compared with high-flow sevoflurane (6 L/min) administration. 
These changes in renal function may become clinically significant or result in 
permanent injuries in patients concomitantly receiving another potentially 
nephrotoxic drug. 
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Aminoglycoside antibiotics can cause tubular necrosis in both humans and 
animals. 12,13 Some currently used aminoglycosides and fluorinated anesthetics, 
such as methoxyflurane and enflurane, have been associated with exacerbation 
of nephrotoxicity in one another. 4,5A4 We did not find any report in which the 
combination of an aminoglycoside and sevoflurane resulted in significantly in- 
creased nephrotoxicity (English language literature databases searched: MEDLINE 
and Ovid; all years searched: key words used: sevoflurane, aminoglycosides, 
gentamicin, and nephrotoxicity), except a handbook 15 that mentions that the 
interaction between sevoflurane and aminoglycosides might be associated 
with increased nephrotoxicity. Therefore, the aim of our study was to investi- 
gate microscopically the effect of the anesthetic sevoflurane on the severity 
of renal histopathologic changes in rabbits pretreated with the aminoglyco- 
side gentamicin. 
MATERIALS AND METHODS 
This single-center, controlled, investigator-blinded, experimental study was 
performed at the Firat University School of Medicine, Elazig, Turkey. The 
design and method of the study were approved by the ethics committee of the 
medical school. Male New Zealand white rabbits, obtained from the institu- 
tion's Center of Experimental Research, weighing 2600 to 3400 g and aged 6 to 
8 months were housed in 120 × 60 x 30-cm steel wire cages and were allowed 
to adapt o the new housing conditions for 7 days (room temperature, 21°C _+ 
1 °C; humidity, 50% _+ 9%). Except for a 4-hour fasting period during the admin- 
istration of anesthesia, the rabbits were fed standard rabbit diet and water ad 
libitum. 
After the adaptation period, the rabbits were randomly divided into 4 groups 
(the gentamicin group, the sevoflurane group, the gentamicin + sevoflurane 
group, and the control group) using the simple random sampling method. 16 The 
gentamicin group received IM gentamicin (Genthaver, Biosel, Istanbul, Turkey) 
10 mg/kg • d -1 for 10 days. Rabbits in the sevoflurane group received saline at a 
volume that was equivalent to the volume of gentamicin that was administered 
for 10 days. On day 11, anesthesia was induced with 8% sevoflurane (Sevorane TM, 
Abbott Laboratories, Abbott Park, Illinois) in 50% oxygen and air using a suit- 
able face mask. When a sufficient depth of anesthesia (loss of eyelash reflex and 
tolerance to tail-clamp stimuli) was reached (without a muscle relaxant), the 
rabbits were intubated (3-mm In) and allowed to breathe spontaneously. End- 
tidal (ET) or end expiratory concentration f sevoflurane was then decreased to 
4% and the rabbits were anesthetized at a flow rate of 4 L/min for 4 hours. Rabbits 
in the gentamicin + sevoflurane group were treated with IM gentamicin at a dosage 
of 10 mg/kg • d -1 for 10 days. On day 11, they were exposed to sevoflurane, as in 
the sevoflurane group. The control group received IM pH-balanced saline solution 
for the duration of the study. The control and gentamicin groups simply received 
no treatment on day 11. 
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For 24 hours posttreatment, the rabbits were observed hourly for the first 
4 hours and then at 4-hour intervals. After day 1, all rabbits were observed at 
6-hour intervals until the end of the study. 
Anesthesia was administered using an anesthesia machine with a semiclosed 
circle system (Dr~iger, Luebeck, Germany) containing soda lime (Sorb-lime, Ber- 
kim, Istanbul, Turkey). The soda lime was changed before each application. ET 
CO 2 and sevoflurane concentrations were monitored by means of a capnometer 
during exposure. 
Twenty-four hours after treatment completion, all rabbits were then anes- 
thetized using thiopental 30 mg/kg IV (Pental sodium, I.E. Ulagay ila~ sanayi, 
Istanbul, Turkey) and were euthanized by cardiac puncture. Kidney specimens 
were obtained within 5 to 10 minutes after the rabbits were euthanized and were 
immediately placed in 10% buffered formalin. Standard paraffin processing and 
sectioning at 5 IJm were performed. Sections were placed on slides, stained with 
hematoxylin and eosin, and identified with a number for examination using light 
microscopy. Specimens were prepared and identified by a pathology technician 
and by other researchers who were not otherwise involved in this study. The 
pathologists were blinded to the source of the specimens. 
A pathologist visually estimated the approximate percentage ofinjured tubule 
cells and graded the severity of the injury as follows: no injury = acute tubular 
necrosis (ATN) in 0% to 1% of tubules; minimal injury = ATN in >1% to <10% of 
tubules; mild injury = ATN in 10% to 25% of tubules; moderate injury = ATN in 
>25% to 50% of tubules; and severe injury = ATN in >50% of tubules (Table I). 17 
Statistical Analysis 
Data are presented as mean (SD). The Kruskal-Wallis and Mann-Whitney U 
tests were used to identify statistically significant differences between the 
groups. A value of P < 0.05 was considered significant. A power calculation 
was carried out to indicate the power of the test to distinguish differences 
between the study groups (based on 10 rabbits per group). The powers of the 
Mann-Whitney Utest to distinguish differences between each of the treatment 
groups (the gentamicin group, the sevoflurane group, and the gentamicin- 
sevoflurane group) and the control group were 92.2%, 87.1%, and 97.1%, 
respectively. The power of the Kruskal-Wallis test to distinguish differences 
between groups was 97.0%. All statistical analysis was performed using SPSS 
version 12.0 (SPSS Inc., Chicago, Illinois). 
RESULTS 
Forty rabbits were randomly assigned to 4 treatment groups of 10 rabbits each 
(mean [SD] age, 7 [0.49] months; mean [SD] weight, 2900 [150] g). No rabbits 
from any group died prior to being euthanized at study end. 
On histopathologic examination, ormal renal histology was observed in the 
control group. In contrast, in the 3 treatment groups, renal proximal tubule 
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Table I. Classification is of renal histopathology based on the percentage of acute tubu- 
lar necrosis (ATN) observed by light microscopy. 
Change by 






No significant pathologic change 
(ATN of 0%-1% of tubules) 
Focal ATN of >1%-<10% of tubules; 
focal vesicular changes in tubular epithelium 
Focal ATN of 10%-25% of tubules; 
focal perinuclear halos and ballooning 
necrosis of tubular epithelium 
ATN of >25%-50% of tubules; widespread 
ballooning necrosis of tubular epithelium; 
definite nuclear degeneration, at least focally; 
proteinaceous material in the tubules; interstitial 
inflammation and tubular regenerative changes 
may not be present 
ATN involving >50% of tubules; changes as in 
category 4, but more widespread 
damage was observed at the corticomedullary junction in 27 (90%) of the rab- 
bits; outer cortex renal tubule injury was also observed in some specimens 
(3 rabbits from the sevoflurane group, 5 rabbits from the gentamicin group, and 
6 rabbits from the gentamicin +sevoflurane group). In the treatment groups, the 
most severe renal damage observed in any rabbit was rated as mild (10%-25%) 
(Table II). 
The mean degree of injury in each of the 3 treatment groups was significantly 
greater compared with that in the control group (all, P < 0.001) (Figure). A sta- 
tistically similar number of rabbits had mild damage to renal tubule cells in all 
3 treatment groups: gentamicin group (4), sevoflurane group (4), and gentami- 
cin + sevoflurane group (7). 
DISCUSSION 
Based on the results of our study, gentamicin and sevoflurane administered 
alone appeared to produce minimal to mild renal injury in rabbits. The admin- 
istration of sevoflurane after treatment with gentamicin resulted in an apparent 
increase in renal damage; however, the between-group differences were not sta- 
tistically significant. 
Inorganic fluoride ions and compound A, the 2 metabolites of the potent 
inhalational nesthetic sevoflurane, have been identified as a potential source 
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Table II. Prevalence of renal tubular necrosis in rabbits administered sevoflurane 
anesthesia, gentamicin treatment, or a combination of both (N = 40). 
None Minimal Mild Moderate Severe 
Group (0%-1%) (>1%-<10%) (10%-25%) (>25%-50%) (>50%) 
Control group* 10 0 0 0 0 
Gentamicin group t 1 5 4 0 0 
Sevoflurane group~ 2 4 4 0 0 
Gentamicin + 
sevoflurane group§ 0 3 7 0 0 
* 1 Administered pH-balanced saline solution at I0 mg/kg • d- for I0 days. 
tAdministered IM qentamicin I0 mg/kg • d -~ for I0 days. 
~Administered pH-~alanced saline solution at I0 mg/kg • d -~ for I0 days. On 11th day, 
administered 4% sevoflurane for 4 hours in 50% oxygen and air at a fresh gas flow rate 
of 4 Llmin. 
§Administered IM gentamicin 10 mg/kg • d -I for 10 days. On 11th day, administered 4% 


















Renal histopathology by mean category score in rabbits treated with genta- 
micin 10 mg/kg- d -1 (gentamicin group), 4% sevoflurane (sevoflurane group), 
and gentamicin 10 mg/kg • d -1 followed by 4% sevoflurane (gentamicin + 
sevoflurane group). The control group received pH-balanced saline solution. 
(See Table I for the definitions of the categories.) *P < 0.001 versus the con- 
trol group. 
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of nephrotoxicity. In some circumstances, prolonged and low-flow sevoflurane 
anesthesia concentrations of these 2 metabolites can achieve higher than nor- 
mal levels. 18,19 However, no evidence of sevoflurane-related nephrotoxicity or
injury has been observed in most studies of the potential nephrotoxic effects 
of sevoflurane in humans. 6,9A9 Some authors have reported increased renal 
excretion of some biochemical markers (such as protein, glucose, 0¢-glutathione- 
S-transferase, and N-acetyl-13-o-glucosaminidase), which may in-dicate nephro- 
toxicity. 1°,11,18 Both inorganic fluoride ions and compound A can cause proxi- 
mal renal tubular necrosis, depending on their concentration a d the duration 
of exposure. 4,8 
Similarly, commonly used aminoglycosides can cause renal proximal tubu- 
lar necrosis. 12,2° Some drugs used in combination with aminoglycosides can 
significantly reduce or increase aminoglycoside toxicity. 21,22 Previous studies 
have observed that aminoglycosides and fluorinated anesthetics potentiate 
nephrotoxic effect in one another. 4,5 Patients with chronic renal insufficiency 
might be resistant o additional toxic effects. In a study by Fish et al, 23 on 
Fischer 344 rats with chronic renal insufficiency, treatment with gentamicin 
was not associated with additional renal injury after induction of anesthesia 
with halothane or enflurane. However, aminoglycosides and potentially neph- 
rotoxic anesthetics can exhibit synergistic effects when administered in com- 
bination to patients with normal renal function. 5,14 Barr et al 4 observed that 
Fischer 344 rats administered a combination of 0.5% methoxyflurane anesthe- 
sia for 3.5 hours and gentamicin 20 mg/kg • d -l had greater enal histologic 
injury and renal function abnormalities compared with rats administered only 
methoxyflurane or gentamicin. Cousins et a124 reported that rats treated with 
a nephrotoxic dose of gentamicin prior to 6 hours of enflurane anesthesia had 
significantly increased renal dysfunction and greater enal injury compared 
with rats that received only gentamicin or enflurane. In a study of 22 humans by 
Motuz et al, 5 aminoglycosides (gentamicin or tobramycin) and enflurane acted 
synergistically, thus increasing the nephrotoxic effect of one another. 
Although blood urea nitrogen and serum creatinine levels did not increase, 
significantly higher urinary excretion of alanine aminopeptidase (an enzyme 
located in the brush border membranes of proximal renal tubules) was 
observed in patients with normal renal function who were administered both 
an aminoglycoside and enflurane compared with patients administered enflu- 
rane alone (P < 0.005). 
A study in humans by Higuchi and Adachi 25 suggested that amikacin (400 mg/d 
for 2 days, administered immediately after the induction of anesthesia) nd low- 
flow (1 L/min) sevoflurane anesthetic did not have a synergistic effect on the 
increase in urinary biochemical markers. The authors uggested that their find- 
ings might have been due to the short treatment period and the use of amikacin 
rather than a different aminoglycoside. Amikacin has a lower nephrotoxic effect 
than gentamicin, 13 and aminoglycoside-induced renal injury is associated with 
dose and duration of treatment. 12 
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Although human proximal tubule cells are resistant o compound A, 26 in- 
organic fluoride-induced nephrotoxicity has been reported in humans after 
methoxyflurane or enflurane anesthesia. 5'14 It has been suggested that after 
sevoflurane anesthesia, no inorganic fluoride-induced nephrotoxicity was detect- 
ed because the plasma fluoride concentration AUC is small due to the rapid 
elimination of sevoflurane and also because sevoflurane undergoes defluorida- 
tion by human renal microsomes at a rate substantially lower than that of 
methoxyflurane. 27 Furthermore, a study by Higuchi et a128 of renal function in 
34 human patients receiving either sevoflurane or isoflurane anesthesia 
observed inorganic fluoride to be the primary cause of sevoflurane-induced 
nephrotoxicity. 
In our study, we performed only microscopic examinations toassess nephro- 
toxicity; we did not measure plasma inorganic fluoride concentrations. We 
believe that inorganic fluoride might have caused the higher levels of renal 
histopathologic damage observed in the gentamicin-sevoflurane group because 
a decrease in urinary excretion of inorganic fluoride has been reported in stud- 
ies of gentamicin and other fluorinated anesthetics (methoxyflurane or enflu- 
rane). 4,24 In the present study, the elimination tu2 of inorganic fluoride might 
have been prolonged due to gentamicin-induced r nal insufficiency in the rab- 
bits. Thus, prolonged exposure to higher levels of inorganic fluoride may have 
caused an increase in the severity of renal injury. 
Administration of sevoflurane for a short period may not be associated with 
nephrotoxicity in patients treated using normal fresh gas flow rates under nor- 
mal circumstances. However, sevoflurane use at low flow rates, at higher con- 
centrations, and for longer periods may produce different results. In a study in 
volunteers, ~8 transient mild injury was detected after only 4 hours of anesthe- 
sia with sevoflurane at a fresh gas flow rate of 2 L/min. Greater apparent renal 
injury in rabbits treated with gentamicin before sevoflurane administration 
was not considered to indicate that these 2 agents potentiated the nephrotoxic 
effect in one another. Therefore, further research is needed to determine if
there is incrementally greater nephrotoxicity due to the interaction of an 
aminoglycoside with sevoflurane. 
CONCLUSION 
In this experimental study of the effects of sevoflurane on the severity of renal 
histopathologic changes, a higher percentage of rabbits were observed to have 
greater renal damage in the gentamicin +sevoflurane group than the other groups. 
However, between-group differences did not reach statistical significance. 
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